Document is current
Any future updates will be listed below
-
Authors
Mortaja, Mahsa
Adams, Stephen R.
McKay, Rana R.
Gutkind, J. Silvio
Advani, Sunil J.
-
Funding
Funding for this research was provided by:
National Institutes of Health (CA215081, CA268513, CA215081)
- License Information
-
More Information
Article History
Received: 1 October 2024
Accepted: 18 March 2025
First Online: 4 April 2025
Competing interests
: M.M.: The author declares no competing interest. S.R.A.: Co-inventor on University of California San Diego filed patent application: “Tumor radiosensitization with antibody conjugates” US Patent Application No. 15/817,017 covering ADC based radiosensitization. R.M.: The author declares no competing interest. J.S.G.: The author declares no competing interest. S.J.A: Co-inventor on University of California San Diego filed patent applications: “Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof” USPTO #10596259, “Tumor radiosensitization with antibody conjugates” US Patent Application No. 15/817,017 covering MMAE and ADC based radiosensitization respectively.
